You have full text access to this Open Access content

Clinical and Translational Science

Cover image for Vol. 9 Issue 2

Edited By: John A. Wagner, MD, PhD

Online ISSN: 1752-8062

Associated Title(s): Clinical Pharmacology & Therapeutics, CPT: Pharmacometrics & Systems Pharmacology

Just Published Articles

  1. You have full text access to this OnlineOpen article
    Pharmacometabolomics in Early-Phase Clinical Development

    T Burt and S Nandal

    Article first published online: 29 APR 2016 | DOI: 10.1111/cts.12396

  2. You have full text access to this OnlineOpen article
    Biotechnology and Translational Medicine

    BW Morrison

    Article first published online: 25 APR 2016 | DOI: 10.1111/cts.12392

  3. You have full text access to this OnlineOpen article
    Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient-Derived iPSC Model

    SP Wyles, SC Hrstka, S Reyes, A Terzic, TM Olson and TJ Nelson

    Article first published online: 22 APR 2016 | DOI: 10.1111/cts.12393

  4. You have full text access to this OnlineOpen article
    Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities (pages 89–104)

    KM Morrissey, TM Yuraszeck, C-C Li, Y Zhang and S Kasichayanula

    Article first published online: 30 MAR 2016 | DOI: 10.1111/cts.12391

  5. You have full text access to this OnlineOpen article
    Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development (pages 74–88)

    T Burt, K Yoshida, G Lappin, L Vuong, C John, SN de Wildt, Y Sugiyama and M Rowland

    Article first published online: 30 MAR 2016 | DOI: 10.1111/cts.12390


Call for Papers

CTS welcomes submission of high-quality, scientifically sound original research papers focused on clinical pharmacology and translational science, including animal, in vitro, in silico, and clinical studies supporting the breadth of drug discovery, development, regulation and clinical use of drugs. Topics of interest include:

- Precision medicine
- Translational medicine, including studies focused on Interrogation/evaluation of mechanism-of-action, human physiology, and interruption of disease pathophysiology
- Hypothesis generating non-clinical and clinical studies, including small clinical trials
- Models of human disease and their therapeutic implications
- Studies that guide Phase 2 dose selection
- Studies that identify or support biomarkers that can be used at any stage of drug development
- Studies that demonstrate effective communication between basic and clinical science
- Regulatory and public health policy implications of translational studies
- PK/PD and quantitative pharmacology as these relate to translational medicine

CTS is now fully Open Access.

The fully Open Access format of the journal, supported by an Article Processing Charge, means that all articles will be made freely available for all to read immediately upon publication. In addition, articles will publish under the Creative Commons License, enabling readers to download the article and share it with others. This platform will allow for and encourage open discourse on published works. ASCPT members receive a discounted rate on their Article Processing Charge. Click here for ASCPT membership details.

American Society for Clinical Pharmacology and Therapeutics

The American Society for Clinical Pharmacology and Therapeutics (ASCPT) was founded in 1900, and consists of over 2,200 professionals whose primary interest is to advance the science and practice of clinical pharmacology and translational medicine for the therapeutic benefit of patients and society. ASCPT is the largest scientific and professional organization serving the disciplines of Clinical Pharmacology and Translational Medicine. To learn more, or to apply for membership, visit: ASCPT assumed ownership and editorial control of CTS from Wiley in early 2015. Under the new arrangements, ASCPT has selected an Editor-in-Chief and editorial team who have taken on all editorial responsibility for CTS, effective with the first 2016 issue. The editorial leadership of CTS, led by John A. Wagner, MD, PhD, as Editor-in-Chief, is comprised of a team of leading experts in the field. If you have any questions about new submissions or general inquiries about the re-launch of the journal, please contact the editorial office at

Why Submit to CTS?


CTS is the first peer-reviewed, truly interdisciplinary journal that helps bridge laboratory discovery with the diagnosis and treatment of human disease, in order to improve human health.

• Indexed in Medline and ISI
• Rigorous and rapid peer review
• Expert group of Associate Editors and Editorial Board
• Authors retain copyright and all content publishes under a Creative Commons License
• All content will be made freely available immediately upon publication, enabling the widest possible audience under the Open Access platform